#1 Hypoglycemia
GLP-1 Receptor Agonists → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 12 studies
Explore evidenceSafety
Last updated: 15 de julio de 2026
Key takeaway
Safety has evidence across 10 diabetes-related interventions, with strongest support for GLP-1 Receptor Agonists, GLP-1 Receptor Agonists and Insulin Delivery Systems.
Evidence status
Extensive ResearchEvidence Base: 81/100
Related Evidence Topics
Evidence Intelligence™
Every evidence topic is generated from structured relationships across diabetes research, including topics, interventions, outcomes, and individual studies.
134
Evidence relationships
146
Studies reviewed
10
Interventions evaluated
Strongest evidence area
GLP-1 Receptor Agonists
Top Evidence Areas
Showing grouped evidence. Expand in Evidence Explorer for detailed intervention-outcome pairs.Open Evidence Explorer
| Rank | Intervention group | Outcome group | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Effectiveness | Action |
|---|---|---|---|---|---|---|---|---|
| #1 | GLP-1 Receptor Agonists | Hypoglycemia | 83/100Strong | 55/100Slightly Positive | 100/100consistent | 12 | weak_positive | Explore evidence |
| #2 | GLP-1 Receptor Agonists | Gastrointestinal Adverse Events | 80/100Strong | 45/100Slightly Negative | 60/100generally_consistent | 5 | weak_negative | Explore evidence |
| #3 | Insulin Delivery Systems | Hypoglycemia | 80/100Strong | 58/100Slightly Positive | 35/100mixed | 6 | weak_positive | Explore evidence |
| #4 | Metformin Therapies | Hypoglycemia | Strong | 70/100Positive | 100/100consistent | 3 | moderate_positive | Explore evidence |
| #5 | SGLT2 Inhibitors | Urinary Tract Infections | Strong | 68/100Positive | 35/100mixed | 3 | moderate_positive | Explore evidence |
| #6 | Sulfonylureas | Hypoglycemia | Strong | 68/100Positive | 67/100generally_consistent | 3 | moderate_positive | Explore evidence |
| #7 | SGLT2 Inhibitors | Hypoglycemia | 72/100Moderate | 69/100Positive | 100/100consistent | 3 | moderate_positive | Explore evidence |
| #8 | DPP-4 Inhibitors | Hypoglycemia | Moderate | 75/100Positive | 100/100consistent | 2 | moderate_positive | Explore evidence |
| #9 | GLP-1 Receptor Agonists | Urinary Tract Infections | 67/100Moderate | 70/100Positive | 35/100mixed | 2 | moderate_positive | Explore evidence |
| #10 | Alpha-glucosidase inhibitors | Hypoglycemia | Emerging | 50/100Neutral | unclear | 1 | neutral | Explore evidence |
#2 Gastrointestinal Adverse Events
GLP-1 Receptor Agonists → Gastrointestinal Adverse Events
Evidence Intelligence™
- EvidenceScore™
- 80
- Strong
- ImpactScore™
- 45
- Slightly Negative
- ConsistencyScore™
- 60
- generally_consistent
Supporting studies: Based on 5 studies
Explore evidence#3 Hypoglycemia
Insulin Delivery Systems → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 80
- Strong
- ImpactScore™
- 58
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 6 studies
Explore evidence#4 Hypoglycemia
Metformin Therapies → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Explore evidence#5 Urinary Tract Infections
SGLT2 Inhibitors → Urinary Tract Infections
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 68
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 3 studies
Explore evidence#6 Hypoglycemia
Sulfonylureas → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 68
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Explore evidence#7 Hypoglycemia
SGLT2 Inhibitors → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 72
- Moderate
- ImpactScore™
- 69
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Explore evidence#8 Hypoglycemia
DPP-4 Inhibitors → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Explore evidence#9 Urinary Tract Infections
GLP-1 Receptor Agonists → Urinary Tract Infections
Evidence Intelligence™
- EvidenceScore™
- 67
- Moderate
- ImpactScore™
- 70
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Explore evidence#10 Hypoglycemia
Alpha-glucosidase inhibitors → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Explore evidencePractical Questions
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Which interventions have the strongest evidence for affecting Safety?
evidence strengthStrong Evidence
Semaglutide have the strongest available evidence signals for Safety.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 79.0 | neutral | ConsistencyScore™ Consistent | 6 studies
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Which interventions are most often studied for Safety?
most studiedEmerging Evidence
Liraglutide, Metformin, and Semaglutide are among the most studied areas in relation to Safety.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 79.0 | neutral | ConsistencyScore™ Consistent | 9 studies
- 2
Liraglutide
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 6 studies
- 3
Metformin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 3 studies
Why this answer: This answer is based on 18 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Where are results mixed or inconsistent for Safety?
consistency issuesModerate Evidence
Results are mixed or unclear for Liraglutide and Tirzepatide in relation to Safety.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: Some evidence reported worsening or harm while other evidence found little or no effect.
Ranked evidence signals
- 1
Tirzepatide
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 2 studies
- 2
Liraglutide
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 2 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Applicability
Population details were available for 1 of 4 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....
Which interventions need more research for Safety?
research gapsEmerging Evidence
40% dextrose gel (200 mg/kg) and 40% dextrose gel (400 mg/kg) need more research in relation to Safety.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
40% dextrose gel (200 mg/kg)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
40% dextrose gel (400 mg/kg)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
How does Semaglutide compare with Semaglutide for Safety?
compareStrong Evidence
Semaglutide have available evidence for Safety, but the comparison requires review of the underlying studies.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 79.0 | neutral | ConsistencyScore™ Consistent | 6 studies
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Interventions Studied for Safety
Intervention categories most commonly studied for safety outcomes.
GLP-1 Receptor Agonists
EvidenceScore™ 61/100
Evidence related to GLP-1 receptor agonist therapies in diabetes studies.
27 Studies
Metformin
EvidenceScore™ 61/100
Evidence related to metformin therapies in diabetes studies.
7 Studies
Liraglutide
EvidenceScore™ 60/100
Evidence related to liraglutide and liraglutide-containing intervention regimens in diabetes studies.
9 Studies
DPP-4 Inhibitors
EvidenceScore™ 59/100
Evidence related to DPP-4 inhibitor therapies in diabetes studies.
7 Studies
Probiotics and Synbiotics
EvidenceScore™ 59/100
Evidence related to probiotic and synbiotic interventions in diabetes studies.
6 Studies
Diabetes Self-Management Education and Support
EvidenceScore™ 59/100
Evidence related to diabetes self-management education and support programs in diabetes studies.
3 Studies
Latest Research
Oral Semaglutide Reduces Heart Failure Events in Diabetes
Published: 1 de enero de 2026
int-semaglutide
out-hyperglycemia-eventsout-hypoglycemia-events
Probiotics reduce GI side effects of metformin without improving metabolic efficacy
Published: 1 de enero de 2026
int-multi-species-synbiotic-fos
out-abnormal-stool-frequencyout-gastrointestinal-symptoms-frequency
Generic semaglutide is as effective as innovator version for diabetes control
Published: 1 de enero de 2026
int-semaglutide
out-adverse-events-incidenceout-hypoglycemia-events
Novel Semaglutide Injection Shows Non-Inferior Glycemic Control
Published: 1 de enero de 2026
int-semaglutide
out-adverse-events-incidenceout-postprandial-hypoglycemia-incidence
Nutritional Therapy and AGIs Improve Postprandial Glucose in Diabetes
Published: 1 de enero de 2026
int-acarboseint-voglibose
out-postprandial-hypoglycemia-incidence
SMS Program Improves Transition from Insulin to GLP-1 RA in Diabetes
Published: 1 de enero de 2026
int-glp-1-receptor-agonists
out-hyperglycemia-eventsout-hypoglycemia-rate
Telemonitoring improves glycemic control in pediatric diabetes
Published: 1 de enero de 2026
int-group-meetingint-usual-lifestyle-care
out-diabetic-ketoacidosis
Ticagrelor monotherapy reduces bleeding in diabetic ACS patients
Published: 1 de enero de 2026
int-aspirinint-ticagrelor-monotherapy-after-3-months-of-dapt
out-bleeding-events
Automated insulin-glucagon delivery reduces hypoglycemia risk
Published: 1 de enero de 2026
int-hybrid-closed-loop-system
out-hypoglycemia-events
BL21 Probiotic Improves Glycemic Control in Type 2 Diabetes
Published: 1 de enero de 2026
int-bifidobacterium-longum-subsp-longum-bl21
out-safety-profile-assessment
Evidence Landscape
Evidence landscape
Each bubble represents an evidence relationship. Position shows effectiveness and EvidenceScoreâ„¢; size reflects study volume.
- Strong evidence
- Moderate evidence
- Limited evidence
Evidence Workspace
Create your evidence workspace
Save evidence topics and organize the research that matters to you.